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The efficacy of a behavioral intervention to reduce human immunodeficiency virus (HIV )
risk behaviors was tested in a randomized, controlled trial with three high-risk popula-
tions at 37 clinics from seven sites across the United States. Compared with the 1855
individuals in the control condition, the 1851 participants assigned to a small-group,
seven-session HIV risk reduction program reported fewer unprotected sexual acts, had
higher levels of condom use, and were more likely to use condoms consistently over a
12-month follow-up period. On the basis of clinical record review, no difference in overall
sexually transmitted disease (STD) reinfection rate was found between intervention and
control condition participants. However, among men recruited from STD clinics, those
assigned to the intervention condition had a gonorrhea incidence rate one-half that of
those in the control condition. Intervention condition participants also reported fewer
STD symptoms over the 12-month follow-up period. Study outcomes suggest that
behavioral interventions can reduce HIV-related sexual risk behavior among low-income
women and men served in public health settings. Studies that test strategies for reducing
sexual risk behavior over longer periods of time are needed, especially with populations
that remain most vulnerable to HIV infection.
The Public Health Service has identified
HIV infection as the most critical present
threat to the nation’s public health. Rates
of HIV infection and acquired immune de-
ficiency syndrome (AIDS) are higher
among racial and ethnic minority popula-
tions, especially African Americans, who
represented 41% of new AIDS cases in
1996. Several trends in the epidemic are
especially disturbing: People are most af-
fected during their productive years, infec-
tion appears to be occurring at increasingly
younger ages, and heterosexual transmission
is rising rapidly, especially among ethnic
minority women (1). These trends under-
score the need for interventions that effec-
tively reduce sexual risk behavior among
ethnic minority heterosexual adults living
in high HIV seroprevalence areas.
In response to directives from Congress,
the National Institute of Mental Health
(NIMH) initiated the NIMH Multisite
HIV Prevention Trial in 1990 to develop a
risk reduction intervention based on cur-
rent best practices in HIV prevention and
to test its efficacy with understudied and
disadvantaged populations at multiple sites
across the United States. This article de-
scribes the main findings of the trial, a study
that included both self-reported and biolog-
ical outcomes and a common protocol at
multiple sites (2).
The trial was implemented in 37 inner-
city, community-based clinics located in
five metropolitan areas. NIMH funded
principal investigators in seven sites: the
Bronx and Harlem, New York City; Man-
hattan and Brooklyn, New York City, and
northern New Jersey; Baltimore, Mary-
land; Atlanta, Georgia; Milwaukee, Wis-
consin; Los Angeles, California; and Or-
ange and San Bernardino counties, Cali-
fornia. Participants were recruited be-
tween January 1994 and February 1996
from three distinct populations at risk
of acquiring HIV and other sexually
transmitted diseases (STDs): men and
women in STD clinics and women attend-
ing health service organizations (HSOs),
mostly primary care clinics (3).
Recruitment procedures. Participants
were screened for HIV-related high-risk
acts with a reliable and sensitive procedure
(4) in the waiting rooms of all recruitment
clinics. Eligibility criteria included the fol-
lowing: age (20 years or older for STD
participants, 18 years or older for HSO
women), engaging in unprotected vaginal
or anal sex in the past 90 days, and having
at least one of the following over the past
90 days: sex with a new sexual partner,
more than one sexual partner, an STD, a
sexual partner they knew also had other
sexual partners, or sex with an injection
drug user or a person infected with HIV.
Most persons reported primarily heterosex-
ual behavior, although 7% of male partici-
pants reported having sex with men during
the 3 months before the baseline interview.
Of 38,893 persons screened, 3706 partici-
pants were randomized, representing 33% of
those eligible at screening. Of these, 1564
men and 862 women were recruited from
STD clinics and 1280 women were recruit-
ed from HSOs.
Statistical power. To determine the
study’s sample sizes, power analyses were
conducted on the basis of two dichotomous
end points: consistent condom use and STD
reinfection rate from chart abstraction data
for male participants recruited through
STD clinics. A goal of 90% power was
chosen to detect differences at the a 5 0.05
level (two-tailed test) between the inter-
vention and control groups within each
population (that is, STD males, STD fe-
males, and female participants in HSOs) at
12 months of follow-up. Sample sizes were
computed to detect a 15% difference in
consistent condom use and a 10% differ-
ence in STD infection rate. It was further
assumed that 95% of subjects randomized
would be at risk and that 72% of these
participants would complete the 12-month
follow-up interview.
Assessment interviews. All participants
were assessed at baseline and again at 3, 6,
and 12 months after the intervention. The
baseline interview assessed sociodemo-
graphic characteristics, physical and mental
health status, STD symptoms, alcohol and
drug use, sexual behavior, and HIV testing.
Assessment interviewers were blind to in-
tervention condition and did not serve as
group facilitators. Moreover, quality control
procedures were rigorously implemented to
ensure accuracy of reported data (2). Com-
pletion rates for follow-up interviews were
82% or greater for participants in both the
intervention and control conditions across
all follow-up assessment points.
Experimental conditions. Participants
assigned to the control condition attended
a 1-hour AIDS education session that in-
cluded a videotape (5) and a question-and-
answer period.
Participants assigned to the intervention
condition were asked to attend seven 90- to
120-min HIV risk reduction sessions, con-
ducted twice weekly in groups of 5 to 15
persons (2). Groups were composed sepa-
rately of male or female participants and
were usually co-led by a male and a female
facilitator with previous group experience
who received extensive training and were
certified before initiating group sessions. Fi-
delity to the intervention protocol was
monitored through periodic site visits and
systematic review of audiotapes of all ses-
sions and videotapes of a random subset of
sessions Participants assigned to the inter-
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vention condition attended an average of
5.2 of the seven sessions (SD 5 2.0), and
63% of participants attended six or all sev-
en sessions
End points. Primary end points for the
trial were (i) self-reported number of unpro-
tected vaginal and anal intercourse acts
during the 90 days before each interview,
(ii) self-reported consistent condom use
during the 90 days before each interview,
(iii) the proportion of vaginal or anal inter-
course acts in which a condom was used
during the 90 days before each interview
(self-reported), (iv) STD reinfection rate
from chart review during the period from
the end of the intervention through the
12-month interview window (male STD
participants only), and (v) point prevalence
of chlamydia and gonorrhea at the 12-
month assessment with DNA amplification
[ligase chain reaction (LCR)] of urine spec-
imens. Secondary end points included (i)
participant self-reports of STD symptoms
during the 90 days before each interview
and (ii) incidence of gonorrhea during the
follow-up period from chart review for STD
participants.
Participants were asked at each inter-
view to indicate the number of people with
whom they had sex during the past 90 days.
The total number of vaginal or anal inter-
course acts (or both) and the total number
of times a condom was used were computed
for each participant by summing events
across all partners. From this information,
the three indices of sexual risk were con-
structed (2).
Statistical methods. Behavioral end
points (number of unprotected vaginal or
anal intercourse acts, proportion of inter-
course acts protected by condoms, and con-
sistent condom use or abstinence) were
analyzed for intervention effects across fol-
low-up assessments and by population. All
models for the number of unprotected in-
tercourse acts were fit to the square root of
the measure. For all analyses, basic model
effects included study population (overall
model only), baseline value of the outcome
measure (except consistent condom use or
abstinence for which all baseline values
were zero, because of study eligibility re-
quirements), study site, and intervention
assignment.
Longitudinal analyses were conducted
by fitting linear repeated measures models
or repeated measures logistic regression
models across follow-up assessments with
generalized estimating equation (GEE)
methodology (6). Participants reporting no
sexual activity during the previous 90 days
at a given follow-up assessment (typically
10 to 12%) were assigned values corre-
sponding to consistent condom use for all
behavioral outcomes. Separate models were
fit to the data for the total sample and for
each study population. Effects for time and
time by experimental condition interac-
tions were added to the basic model. Tests
of intervention effects at each of the three
follow-up assessment points and overall, as
well as tests of time by intervention condi-
tion interactions, were computed by Wald
x2 tests.
Analysis of covariance (ANCOVA)
models were fit to each behavioral outcome
measured at the 12-month assessment to
assess whether the intervention effect re-
mained when missing 12-month outcome
values were imputed, with three imputation
methods: (i) a last observation forward ap-
proach for all participants who completed
the baseline and at least one follow-up as-
sessment, (ii) a method (7) based on re-
sponse within strata defined by outcomes or
nonresponse at 3- and 6-month follow-ups,
and (iii) a method that uses baseline values
to replace missing data at the 12-month
assessments.
The contribution of intervention condi-
tion attendance to the outcome effects was
examined by fitting ANCOVA models to
each 12-month follow-up outcome with a
three-level attendance indicator (control,
attended five or fewer sessions, or attended
six or seven sessions).
Differential intervention effects across
subgroups defined by participant character-
istics were assessed by including baseline
covariate effects and intervention condi-
tion by covariate interactions in ANCOVA
models fit to each outcome measured at the
12-month follow-up assessment.
Self-reports were used to determine the
presence of STD-related symptoms during
follow-up. For participants recruited in STD
clinics, indicators of incident STDs both
overall and by type (gonorrhea, chlamydia,
syphilis, trichomoniasis, and nongonocco-
cal urethritis) at any time during the 12-
month follow-up period were created from
chart abstraction data. Dichotomous indi-
cators of gonorrhea and chlamydia were
also created on the basis of urine tests com-
pleted at the 12-month follow-up assess-
ment. For each of these indicators, the in-
tervention and control condition results
were compared by Cochran-Mantel-Haens-
zel x2 tests stratified by study population
(overall test only) and study site.
Who participated in the trial? The large
majority of participants were African
American or Hispanic; most were single,
unemployed, and treated previously for
STDs, and all were at high behavioral risk
for HIV (Table 1). The sociodemographic
and sexual behavior characteristics of con-
trol and intervention condition participants
were very similar. The two groups differed
slightly in condom use rate at baseline; a
slightly higher percentage (83.7%) of con-
trol condition participants than interven-
tion condition participants (80.4%) report-
ed that they used condoms half or less of the
time. Of those tested for HIV, 54% dis-
closed the results of the test (8).
Did the intervention produce changes
in sexual behavior? Reported frequency of
unprotected intercourse acts decreased in
Fig. 1. Mean proportion of condom use overall at
baseline and at 3-, 6-, and 12-month follow-ups
by intervention assignment. Brackets at each time
point show 95% confidence limits on the mean.
Means increased from 0.21 to 0.23 at baseline to
about 0.60 for the intervention condition during
follow-up and 0.45 to 0.48 for the control condi-
tion. The effect size was 0.47 at 3 months, 0.36 at
6 months, and 0.31 at 12 months.
Table 1. Sociodemographic and risk behavior
characteristics for persons eligible at baseline and





,25 years of age 24.8 25.2
Hispanic 25.6 25.2
African American* 73.9 74.0
$ High school 54.8 55.5




(90 days) 61.6 59.4
31 partners
(90 days) 35.0 34.2
Ever HIV tested 82.8 82.8
$11 risky acts
(90 days) 53.1 51.9
0% condom use
(90 days) 44.7 44.2
0 to 50% condom use
(90 days) 83.7† 80.4
Drug use
(90 days) 53.5 53.2
Injected drugs
(90 days) 6.7 6.9
Ever had STD 73.1 73.0
Sample size 1855 1851
*Includes African Americans of Hispanic descent.
†Indicates a significant difference between the control and
intervention conditions at the P , 0.05 level, with a x2 test
of association.
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the follow-up period for participants in both
study conditions. Participants in the inter-
vention condition reduced their frequency
of unprotected intercourse acts significantly
more than control condition participants at
each follow-up assessment (P ,0.0001
across all follow-up points; Table 2). Mean
frequency of unprotected intercourse acts
among intervention condition participants
declined by about 50% from baseline levels
to 12.9 acts at 3 months, 12.5 acts at 6
months, and 12.0 acts at the 12-month
follow-up, reflecting intervention effect siz-
es of 20.29 at the 3-month follow-up and
20.21 at the 12-month follow-up. Longitu-
dinal analyses also indicated a significant
overall decrease in unprotected intercourse
acts for the intervention condition. Very
similar patterns of change were found across
the three study populations.
Although levels of condom use in-
creased over time among control condition
participants, the increase in condom use by
participants who received the intervention
was significantly greater (P ,0.0001 across
all follow-up points; Table 3 and Fig. 1).
Among intervention condition members
overall, only 23% of intercourse acts in the
90 days preceding the baseline assessment
were protected by condoms. Condom use
increased to 63% of all intercourse acts at
3-month follow-up and never declined be-
low 60% in any subsequent follow-up, re-
flecting effect sizes of 0.47 at the 3-month
follow-up and 0.31 at the 12-month follow-
up. Longitudinal analyses again showed sig-
nificantly greater condom use overall
among the intervention condition partici-
pants. Similar patterns were evident in all
three of the study populations.
At baseline, enrollment criteria ensured
that no study participants were consistent
condom users (or sexually abstinent) in the
previous 90 days. At the 3-month follow-
up, 42.0% of intervention condition partic-
ipants were consistently using condoms or
were abstinent; consistent condom use or
abstinence was reported by 44.1% of inter-
vention condition members at the 6-month
follow-up and 43.4% at the 12-month fol-
low-up. Although there was also an increase
Table 2. Number of unprotected intercourse acts in the 90 days before baseline
and at 3-, 6-, and 12-month follow-ups by intervention type and population. The
table is based on all nonmissing visits at each time point. All participants included
in this table and Tables 3 and 4 had to have at least one follow-up interview.
Because 90% of the participants completed one or more follow-up interviews,
the sample size for the baseline results was about 90% of that of the full sample.
Assessments occurring outside of allowable windows for each follow-up period
(4 to 5%) were excluded from behavioral outcome analyses, with windows de-
fined as follows: 2 to 4.5 months for 3-month follow-up assessments, 4.5 to 8
months for 6-month assessments, and 10.5 to 15 months for 12-month assess-
ments. Additionally, a very few participants at each time point were unable to
specify either the number of times they had intercourse or the number of times
they used a condom or both, so the behavioral outcomes could not be calculated
for that visit. C, control; I, intervention.
Baseline 3 months 6 months 12 months Overall
intervention
effect P value†N Mean SE N Mean SE P value* N Mean SE P value* N Mean SE P value*
Overall‡
C 1,673 23.9 (0.8) 1,427 17.9 (0.9) 0.0001 1,501 15.0 (0.7) 0.0001 1,453 16.7 (1.0) 0.0001 0.0001
I 1,679 24.7 (0.9) 1,520 12.9 (1.0) 1,533 12.5 (0.7) 1,473 12.0 (0.7)
STD-male
C 657 25.0 (1.4) 550 19.0 (1.8) 0.0001 583 15.3 (1.3) 0.0003 559 15.7 (1.2) 0.0004 0.0001
I 684 25.0 (1.4) 602 12.3 (1.9) 612 11.6 (1.1) 586 11.3 (1.0)
STD-female
C 401 26.5 (2.0) 354 18.9 (1.5) 0.0001 363 15.9 (1.4) 0.02 337 20.4 (3.2) 0.007 0.0001
I 388 25.2 (1.9) 357 13.2 (1.5) 351 14.9 (2.0) 340 13.6 (1.6)
HSO Women
C 615 21.1 (1.1) 523 16.1 (1.1) 0.0001 555 14.1 (1.0) 0.0004 557 15.5 (1.2) 0.0001 0.0001
I 607 24.1 (1.5) 561 13.5 (1.2) 570 12.0 (1.0) 547 11.8 (1.0)
*P value for a test of intervention compared with control at the specified follow-up visit from longitudinal models fit to square-root transformed outcome. Separate models were fit
to the data overall and for each study population and included effects for baseline value of the end point, intervention assignment, site, study population (total only), time, and time
by intervention assignment interaction. †P value for an overall test of intervention compared with control. Longitudinal models were fit as above excluding time by intervention
assignment interaction. ‡Over the three study populations.
Table 3. Proportion of condom use in the 90 days before baseline and at 3-, 6-, and 12-month follow-ups by intervention type and population. See Table 2
legend. C, control; I, intervention.
Baseline 3 months 6 months 12 months Overall
intervention
effect P value†N Mean SE N Mean SE P value* N Mean SE P value* N Mean SE P value*
Overall‡
C 1,673 0.21 (0.01) 1,427 0.45 (0.01) 0.0001 1,501 0.48 (0.01) 0.0001 1,453 0.48 (0.01) 0.0001 0.0001
I 1,679 0.23 (0.01) 1,520 0.63 (0.01) 1,533 0.62 (0.01) 1,473 0.60 (0.01)
STD-male
C 657 0.24 (0.01) 550 0.51 (0.02) 0.0001 583 0.53 (0.02) 0.0001 559 0.52 (0.02) 0.0001 0.0001
I 684 0.28 (0.01) 602 0.69 (0.02) 612 0.67 (0.02) 586 0.64 (0.02)
STD-female
C 401 0.21 (0.01) 354 0.40 (0.02) 0.0001 363 0.46 (0.02) 0.0001 337 0.44 (0.02) 0.0001 0.0001
I 388 0.20 (0.01) 357 0.60 (0.02) 351 0.58 (0.02) 340 0.59 (0.02)
HSO women
C 615 0.20 (0.01) 523 0.40 (0.02) 0.0001 555 0.45 (0.02) 0.0001 557 0.45 (0.02) 0.0001 0.0001
I 607 0.19 (0.01) 561 0.58 (0.02) 570 0.59 (0.02) 547 0.58 (0.02)
*P value for a test of intervention compared with control at the specified follow-up visit from longitudinal models. Separate models were fit to the data overall and for each study
population and included effects for baseline value of the end point, intervention assignment, site, study population (total only), time, and time by intervention assignment
interaction. †P value for an overall test of intervention compared with control. Longitudinal models were fit as above excluding time by intervention assignment
interaction. ‡Over the three study populations.
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in consistent condom use among control
condition members (that is, about one-third
of control participants reported consistent
condom use at the 12-month follow-up),
the magnitude of change was significantly
greater among intervention condition par-
ticipants (P , 0.0001 at each follow-up
point and longitudinally; Table 4). The
three populations showed similar patterns.
For all behavioral outcomes, the same pat-
tern of results emerged when missing values
were imputed (9).
Participants who attended more inter-
vention sessions exhibited greater magni-
tudes of behavior change. A significant in-
tervention by dose (number of sessions
attended) interaction was observed for
number of unprotected intercourse acts,
proportion of condom use, and consistent
condom use or abstinence. For example, the
mean number of unprotected intercourse
acts at the 12-month follow-up was 16.7
acts for participants in the control condi-
tion, compared with 13.2 acts for interven-
tion condition participants who had attend-
ed five or fewer sessions (P 5 0.03) and
11.2 acts for those who had attended six or
all seven sessions (P , 0.0001).
ANCOVA was used to assess the con-
sistency of the intervention effect across
subgroups defined by baseline characteris-
tics. Differential effects, with respect to the
three behavioral outcome measures at the
12-month follow-up, were not observed
across subgroups defined by age, education,
race or ethnicity, baseline alcohol abuse
symptoms, drug use (past 90 days), commer-
cial or survival sex (past 90 days), unwanted
sexual activity, or mental health service use
(past 90 days).
Did the intervention produce change in
rates of incident STDs? About one in three
(34.6%) control condition members report-
ed experiencing symptoms indicative of an
STD at one or more follow-up points, sig-
nificantly higher than the rate of 27.9%
among intervention condition members
(P 5 0.001; Table 5). This significant pat-
tern was found consistently across the three
study populations.
Overall, about 9% of the participants
recruited from STD clinics evidenced an
incident STD on the basis of clinic chart
review (Table 5). Although no difference
was observed between intervention or con-
trol conditions, aggregating data may mask
outcome effects because, in the United
States, incidence of sexually transmitted
disease differs by age and gender (10). Gon-
orrhea is more prevalent among men than
women over the age of 24 years, and it is
generally more symptomatic in men than
women (11). Additionally, gonorrhea is
easily detected by virtually all public health
clinics (12). Thus, incident gonorrhea was
examined separately among male partici-
pants. Chart records indicated that 6.4% of
STD clinic control condition men were
treated for incident gonorrhea in the fol-
low-up year compared with only 3.6%
among intervention condition STD clinic
men (P , 0.03).
The LCR urinalysis at 12-month follow-
up revealed point prevalence for gonorrhea
of 1.5% among control condition members
and 0.9% among intervention condition
members. Although in a direction consis-
tent with the other measures of gonorrhea
follow-up incidence and consistent across
Table 4. Percentage of consistent condom use or abstinence in the 90 days
before baseline and at 3-, 6-, and 12-month follow-ups by intervention type and
population. The table is based on all nonmissing visits at each time point. Partic-
ipants reporting consistent condom use at baseline were ineligible for the trial;
thus, the percentage of participants reporting consistent condom use is zero at
baseline by definition. Also see Table 2 legend. C, control; I, intervention.
Baseline 3 months 6 months 12 months Overall
intervention
efffect
P value†N Percentage SE N Percentage SE P value* N Percentage SE P value* N Percentage SE P value*
Overall‡
C 1,673 0 1,427 27.3 (1.2) 0.0001 1,501 33.2 (1.2) 0.0001 1,453 34.4 (1.3) 0.0001 0.0001
I 1,679 0 1,520 42.0 (1.3) 1,533 44.1 (1.3) 1,473 43.4 (1.3)
STD-male
C 657 0 550 30.6 (2.0) 0.0001 583 36.0 (2.0) 0.0001 559 36.9 (2.0) 0.004 0.0001
I 684 0 602 47.2 (2.0) 612 47.1 (2.0) 586 45.1 (2.1)
STD-female
C 401 0 354 26.0 (2.3) 0.0009 363 32.5 (2.5) 0.08 337 32.9 (2.6) 0.03 0.002
I 388 0 357 37.5 (2.6) 351 39.0 (2.6) 340 41.2 (2.7)
HSO women
C 615 0 523 24.7 (1.9) 0.0001 555 30.8 (2.0) 0.0001 557 32.9 (2.0) 0.0004 0.0001
I 607 0 561 39.2 (2.1) 570 44.0 (2.1) 547 43.0 (2.1)
*P value for a test of intervention compared with control at the specified follow-up visit from longitudinal models. Separate models were fit to the data overall and for each study
population and included effects for baseline value of the end point, intervention assignment, site, study population (total only), time, and time by intervention assignment
interaction. †P value for an overall test of intervention compared with control. Longitudinal models were fit as above excluding time by intervention assignment
interaction. ‡Over the three study populations.
Table 5. Results of symptoms, clinical chart review (diagnosed with at least one STD), and urine
specimen analysis by population and intervention type. Table gives percentage of participants. C,
control; I, intervention.
Symptoms* Clinical chart review Urine specimen
N Percentage N All STDs† (%) GC (%) N CT (%) GC (%)
Overall
C 1,729 34.6‡ 904 9.4 5.0‡ 1,296 2.8 1.5
I 1,722 27.9 922 9.1 3.0 1,285 2.9 0.9
STD-male
C 692 17.5‡ 576 9.9 6.4‡ 499 1.8 2.0
I 706 12.5 583 8.2 3.6 505 3.6 1.0
STD-female
C 413 47.9‡ 328 8.5 2.4 313 1.9 1.9
I 400 41.0 339 10.6 2.1 288 2.1 1.4
HSO women
C 624 44.7‡ –§ – – 484 4.3 0.8
I 616 37.0 – – – 492 2.6 0.6
*At any follow-up. †Gonorrhea (GC), chlamydia (CT ), nongonoccocal urethritis (for males only), syphilis, and
trichomoniasis. ‡Control and intervention significantly different at 0.05 level. §No biological abstraction was
done for women recruited from HSOs.
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the three study populations, this difference
was not statistically significant.
Discussion. Relative to participants in a
control condition who received only a sin-
gle-session AIDS education program, men
and women who received a seven-session
group HIV prevention intervention that fo-
cused on attitude, skill, and risk reduction
behavior change strategies reported greater
reductions across a range of sexual risk in-
dicators. Because consistent condom use
has been linked to reductions in HIV sero-
incidence (13–15) and because reductions
in frequency of unprotected sex also predict
lower levels of STD incidence, the behav-
ioral effects of the intervention carry con-
siderable public health importance.
The findings from this trial provide some
direct evidence that the intervention also
reduced disease outcomes. Relative to con-
trol condition members, participants who
received the group intervention were less
likely to report symptoms indicative of syn-
dromal STDs through the follow-up period.
Clinic chart data available for men and
women recruited from STD clinics were
used to identify new STDs in the follow-up
period, incorporating clinician diagnosis,
serology, and laboratory culture tests per-
formed in the clinics. These data revealed
similar overall rates of STD reinfection
among intervention and control partici-
pants. However, for gonorrhea in men—an
STD with high incidence in this popula-
tion, which produces symptoms in men that
usually result in treatment-seeking—lower
incidence was observed among intervention
condition participants compared with con-
trols. Unexpectedly low point prevalence of
gonorrhea and chlamydia at the 12-month
follow-up limited the likelihood of observ-
ing between-group differences. However,
the pattern of LCR findings on gonorrhea
was consistent with the other STD symp-
tom, diagnosis, and behavioral change data.
Because HIV infection may be acquired
during unprotected intercourse and is a dis-
ease linked to behavior, change in sexual
behavior practices is an appropriate out-
come in HIV prevention studies. Of neces-
sity, these practices must be measured
through participants’ self-reports of their
sexual behavior. Previous research has es-
tablished the validity and reliability of sex-
ual risk behavior self-reports (16, 17). The
current study sought to minimize threats to
the reliability and validity of participants’
reports of their sexual practices by pilot
testing of questions to elicit sexual behavior
data and training interviewers to elicit sex-
ual practice reports in a nonjudgmental and
unbiased manner. The consistency and
magnitude of change found across multiple
indicators of sexual risk behavior—includ-
ing frequency of unprotected intercourse,
levels of condom use, and patterns of con-
sistent condom use—strengthen confidence
in the behavior change outcomes produced
by the intervention.
Two findings of the study warrant at-
tention in future research. First, although
reductions in sexual risk behavior in the
intervention condition were significantly
greater than those in the control condi-
tion, risk behavior also decreased among
control condition members. A large por-
tion of the participants were recruited
from STD clinics, where they are coun-
seled to reduce their risky behavior. Ad-
ditionally, the process of self-evaluation,
as would occur during in-depth assessment
of risk behavior, may enhance motivation
to change.
No past trials of group HIV preventive
interventions have examined changes in
both self-reported sexual risk practices and
markers of subsequent disease incidence.
The use of incident STDs as an indicator of
the effectiveness of HIV prevention pro-
grams has often been advocated (18). STD
symptom self-reports, shown in past re-
search to correlate highly with laboratory
tests for STDs (3), may serve as another
indicator of disease associated with sexual
behavior. Medical chart reviews—especial-
ly when supported by clinical evidence of
disease and laboratory test findings, as in
this study—yield additional data that com-
plement self-reported sexual behavior.
However, chart and symptom data are im-
perfect because many STDs are asymptom-
atic, especially among women, and not all
patients with STDs seek treatment or are
treated consistently at the same clinic. Al-
though diagnostic procedures such as the
LCR assay of urine can detect certain STDs
with considerable sensitivity, they can de-
tect only diseases present at the time of
testing. Incident disease would not be de-
tected in individuals who acquired and re-
ceived treatment for an STD earlier in a
follow-up period. For these reasons, re-
search on the effectiveness of interventions
to reduce sexual risk behavior should use a
variety of outcome indicators.
Finally, several factors may have reduced
the likelihood of observing between-group
differences on biological outcome indica-
tors. Notwithstanding the strict intake cri-
teria and the known high risk behavior
among STD clinic populations, observed
rates of STDs were lower than anticipated.
Only 75% of the medical charts of STD
clinic participants were available for review,
although chart recovery rates were the same
across conditions. Some participants may
have been treated for STDs at alternative
clinical settings, further attenuating the
amount of measurable disease. In sum, al-
though imperfect, biological measures of
STDs are an important element of compre-
hensive evaluation of HIV prevention in-
terventions because they are not subject
to the limitations of self-reported sexual
behavior.
Collectively, these findings indicate that
the intervention was successful in reducing
HIV-related sexual risks over a 1-year peri-
od. Nonetheless, it is equally important that
strategies be developed to maintain longer
term behavior changes in low-income, ur-
ban minority populations. Even if the re-
ductions in HIV-related behavior observed
in this study were maintained for only 1
year, however, they would still have a pro-
found cost-effective public health impact in
terms of the numbers of cases of HIV (and
other STDs) averted in communities that
adopted this intervention (19). These re-
sults lend support to the desirability of de-
livering behavioral, skill-based interven-
tions in settings serving persons at high risk
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